Komposition:
Anwendung:
Wird bei der Behandlung verwendet:
Medizinisch geprüft von Oliinyk Elizabeth Ivanovna, Apotheke Zuletzt aktualisiert am 26.06.2023
Achtung! Die Informationen auf der Seite sind nur für medizinisches Fachpersonal! Die Informationen werden in öffentlichen Quellen gesammelt und können aussagekräftige Fehler enthalten! Seien Sie vorsichtig und überprüfen Sie alle Informationen auf dieser Seite!
Top 20 Medikamente mit den gleichen Inhaltsstoffen:
Adults:
Odnatron Melt is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy.
Odnatron Melt is indicated for the prevention of post-operative nausea and vomiting (PONV).
For treatment of established PONV, administration by injection is recommended.
Paediatric Population:
Odnatron is indicated for the management of chemotherapy-induced nausea and vomiting (CINV) in children aged >6 months
No studies have been conducted on the use of orally administered ondansetron in the prevention and treatment of PONV in children aged >1 month, administration by IV injection is recommended for this purpose.
- Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin ≥50 mg/m2.
- Prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
- Prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen.
- Prevention of postoperative nausea and/or vomiting. As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and/or vomiting must be avoided postoperatively, Odnatron tablets are recommended even where the incidence of postoperative nausea and/or vomiting is low.
Adults:
- Prophylaxis of acute nausea and vomiting induced by moderately emetogenic chemotherapy.
- Prophylaxis and treatment of delayed nausea and vomiting induced by moderately to highly emetogenic chemotherapy.
- Prophylaxis and treatment of acute and delayed nausea and vomiting induced by highly emetogenic radiotherapy.
- Prophylaxis and treatment of post-operative nausea and vomiting (PONV).
Paediatric Population:
- Management of chemotherapy-induced nausea and vomiting in children aged >6 months.
- Prophylaxis and treatment of post-operative nausea and vomiting (PONV) in children aged >4 years.
However, we will provide data for each active ingredient
